A Phase 1 study of MOMA-341 in advanced solid tumors

Study Description

A study evaluating the safety and effectiveness of an investigational drug called MOMA-341 in patients with advanced or metastatic solid tumors

Study Details

Registry ID:

NCT06974110

Conditions:

Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer, dMMR Cancer

Phase:

Phase 1

Target Enrollment:

132 participants

Start Date:

July 16, 2025

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (14 sites)

• Investigative Site #131
  Raleigh, North CarolinaUnited States, United States
• Investigative Site #128
  Tampa, FloridaUnited States, United States
• Investigative Site #120
  Detroit, MichiganUnited States, United States
• Investigative Site #110
  St Louis, MissouriUnited States, United States
• Investigative Site #129
  Houston, TexasUnited States, United States
• Investigative Site #132
  Phoenix, ArizonaUnited States, United States
• Investigative Site #119
  Perth, Western AustraliaAustralia, Australia
• Investigative Site #101
  San Diego, CaliforniaUnited States, United States
• Investigative Site #121
  Portland, OregonUnited States, United States
• Investigative Site #125
  Adelaide, South AustraliaAustralia, Australia
• Investigative Site #126
  Clayton, VictoriaAustralia, Australia
• Investigative Site #123
  Westmead, New South WalesAustralia, Australia
• Investigative Site #123
  WestmeadAustralia, Australia
• Investigative Site #122
  Sydney, New South WalesAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →